Monitor for COVID-19 vaccine resistance evolution during clinical trials

Although less common than the evolution of antimicrobial drug resistance, vaccine resistance can and has evolved. How likely is it that COVID-19 vaccines currently in development will be undermined by viral evolution? We argue that this can be determined by repurposing samples that are already being...

Descripción completa

Detalles Bibliográficos
Autores principales: Kennedy, David A., Read, Andrew F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Perspective
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7676675/
https://www.ncbi.nlm.nih.gov/pubmed/33166303
http://dx.doi.org/10.1371/journal.pbio.3001000
_version_ 1783611820012994560
author Kennedy, David A.
Read, Andrew F.
author_facet Kennedy, David A.
Read, Andrew F.
author_sort Kennedy, David A.
collection PubMed
description Although less common than the evolution of antimicrobial drug resistance, vaccine resistance can and has evolved. How likely is it that COVID-19 vaccines currently in development will be undermined by viral evolution? We argue that this can be determined by repurposing samples that are already being collected as part of clinical trials. Such information would be useful for prioritizing investment among candidate vaccines and maximizing the potential long-term impact of COVID-19 vaccines.
format Online
Article
Text
id pubmed-7676675
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-76766752020-12-02 Monitor for COVID-19 vaccine resistance evolution during clinical trials Kennedy, David A. Read, Andrew F. PLoS Biol Perspective Although less common than the evolution of antimicrobial drug resistance, vaccine resistance can and has evolved. How likely is it that COVID-19 vaccines currently in development will be undermined by viral evolution? We argue that this can be determined by repurposing samples that are already being collected as part of clinical trials. Such information would be useful for prioritizing investment among candidate vaccines and maximizing the potential long-term impact of COVID-19 vaccines. Public Library of Science 2020-11-09 /pmc/articles/PMC7676675/ /pubmed/33166303 http://dx.doi.org/10.1371/journal.pbio.3001000 Text en © 2020 Kennedy, Read http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Perspective
Kennedy, David A.
Read, Andrew F.
Monitor for COVID-19 vaccine resistance evolution during clinical trials
title Monitor for COVID-19 vaccine resistance evolution during clinical trials
title_full Monitor for COVID-19 vaccine resistance evolution during clinical trials
title_fullStr Monitor for COVID-19 vaccine resistance evolution during clinical trials
title_full_unstemmed Monitor for COVID-19 vaccine resistance evolution during clinical trials
title_short Monitor for COVID-19 vaccine resistance evolution during clinical trials
title_sort monitor for covid-19 vaccine resistance evolution during clinical trials
topic Perspective
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7676675/
https://www.ncbi.nlm.nih.gov/pubmed/33166303
http://dx.doi.org/10.1371/journal.pbio.3001000
work_keys_str_mv AT kennedydavida monitorforcovid19vaccineresistanceevolutionduringclinicaltrials
AT readandrewf monitorforcovid19vaccineresistanceevolutionduringclinicaltrials

Ejemplares similares